Sophie Mukadam - Nov 18, 2025 Form 4 Insider Report for Benitec Biopharma Inc. (BNTC)

Role
Chief Operating Officer
Signature
/s/ Sophie Mukadam
Stock symbol
BNTC
Transactions as of
Nov 18, 2025
Transactions value $
$0
Form type
4
Date filed
11/20/2025, 05:37 PM
Previous filing
Jan 3, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mukadam Sophie Chief Operating Officer C/O BENITEC BIOPHARMA INC., 3940 TRUST WAY, HAYWARD /s/ Sophie Mukadam 2025-11-20 0002050122

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BNTC Options (right to buy) Award $0 +500K $0.00 500K Nov 18, 2025 Common Stock 500K $13.53 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock options will vest in 16 substantially equal quarterly installments commencing on March 31, 2026.